Combination immunotherapy treatment significantly improves disease-free survival following surgery in patients with the most common type of kidney cancer, according to new research. Results from the ...

We are a world-leading cancer research institute, a charity, and a member institution of the University of London. Public donations and clinical partnerships are helping us to make the discoveries ...

Need to find a specific expert or member of a research group or division? Just search by role, division, name or browse our researchers A-Z.

Research, projects and publications in this group We are a multidisciplinary group of statisticians, methodologists, clinical trial programme managers, trial managers and data scientists within the ...

The overuse of CT scans could cause over 100,000 cases of cancer in the US – with almost 10,000 cases in children, researchers have warned. According to a new modelling study, published in the journal ...

Image: DNA sequence. Credit: The Institute of Cancer Research, London. A spit test, where a sample can be collected at home, is more accurate at identifying future risk of prostate cancer for one ...

Image: Person walking towards the beach. Credits: Pixabay. Most people are aware of the benefits of exercise – it has been associated with improvements in overall health for some time. It makes sense ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...

A spit test, where a sample can be collected at home, is more accurate at identifying future risk of prostate cancer for some men than the current standard PSA blood test, a new study reports. Results ...

Image: A scanning electron microscope image of a prostate cancer cell. Credit: Anne Weston, Francis Crick Institute. CC BY-NC 4.0. At The Institute of Cancer Research, London, we often refer to ...

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. The drug capivasertib combined with hormone therapy ...

The latest major breakthrough in cancer is a drug called capivasertib, which has shown ‘remarkable’ results against advanced breast cancer in its first phase III trial. Results released at the ...